One of our guiding principles has always been that our people (consultants, employees, etc.) are as MUCH of a client to us as our companies and contacts. Everyone is treated with the same amount of importance. Why? This supports retention, encourages long-term decision making and drives lasting relationships based upon mutually beneficial outcomes. No one is a pawn or tool supporting our agenda. Rather, our agenda is you. Its quite simple really.
Conjugate Group
商务咨询服务
Waltham,Massachusetts 2,157 位关注者
Flexible Drug Development for fast moving biopharma firms.
关于我们
The Conjugate Group provides flexible drug development services and resources. The scope of our services ranges from strategic consulting and functional staff augmentation to comprehensive, deliverable-based solutions starting from IND Enabling through Commercial launch. Our people are industry veterans with numerous accolades and accomplished careers in their respective areas of expertise. These functions include: Program and Portfolio Management, Medical Writing, CMC, Regulatory Affairs and Submissions, Quality Assurance (GxP), Medical Affairs, Clinical Operations, Biostatistics and Programming, and more.
- 网站
-
https://www.conjugategroup.com/
Conjugate Group的外部链接
- 所属行业
- 商务咨询服务
- 规模
- 51-200 人
- 总部
- Waltham,Massachusetts
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Consulting、Pharmaceutical Development、Study Design、Program Management、CMC、Regulatory Affairs、Quality Assurance、Medical Affairs、Clinical Operations、Biostatistics、Partnerships和Alliance Management
地点
-
主要
330 Bear Hill Rd.
304
US,Massachusetts,Waltham,02451
Conjugate Group员工
-
Patrick Gill
Building innovative and creative solutions to bridge the gap between resources, timelines and budget, for drug development and device companies and…
-
Jesse Nandhavan
Representing the best clinical development professionals in the biotech and pharmaceutical industries
-
Sean Malkus
Drug Development Strategy and Execution
-
Louis Farese
Connecting Top Talent with Biotech & Pharma Leaders
动态
-
We hope everyone is enjoying the beginning of 2025, hard to believe its already February- and in Waltham, MA it FEELs like February... Just a quick update regarding our progress/growth. 2024 was marked by key staff additions, process & system maturations and increased capability to deliver our services. Our Flexible Drug Development model is far stronger/has more power today than it did at the beginning of 2024. This is very exciting for us and the people we serve. We added roughly 2 dozen new clients diversifying our business. We grew on the top line by over 30% in a 'down' market! This is validating for us. We are excited for 2025 and beyond ready to meet the challenges of our dynamic clients. Give us an opportunity if you have one. We will work hard for you. Andrew Young #conjugategroup #flexibledrugdevelopment
-
As Sean Malkus says, this echoes much of what we have heard from our clients in recent weeks/months. We'd love to hear from you on the trends you are seeing in your company, and talk about how we can help you achieve your development milestones in 2025 through Flexible Drug Development! #FlexibleDrugDevelopment #clinicaltrials
The Deloitte 2025 Life Sciences Outlook echoes the trends and sentiments we've been discussing with clients. There is a nearly universal (if cautious) sense of optimism for the year ahead. From the normalization of the IPO and investment landscape to breakthroughs in technology, these conversations reveal exciting opportunities for innovation and growth. With the rebuilding phase of 2024 behind us, the industry is poised for a more robust 2025! Key Highlights from the Report: **Optimism in the Industry:** 75% of global life sciences executives, including those from biopharma and pharmaceutical companies, express optimism about 2025. Among them, 68% anticipate revenue growth, and 57% foresee margin expansions driven by technological advancements and evolving consumer expectations. **AI-Driven Digital Transformation:** Generative AI and cloud computing are revolutionizing product development and operations in biopharma and pharmaceuticals. Approximately 60% of pharmaceutical executives recognize AI as essential for advancing drug discovery, accelerating clinical trials, and streamlining supply chains. **Oncology, Rare Disease, and the GLP-1 Landscape:** The prominence of GLP-1 drugs in 2024 reflects the sector’s growth, extending applications beyond Obesity and Diabetes into areas like Sleep Apnea and NASH/MASH. Oncology and Rare Disease continue to attract significant investments, bolstered by favorable regulations and a growing emphasis on personalized medicine. Innovations in biomarkers and genomics, amplified by AI, are driving these advancements to improve patient outcomes. **Strategic Partnerships:** Forming alliances and strategic partnerships remains critical for strengthening pipelines and building resilience against market uncertainties. At Conjugate Group, we have noted these trends through our conversations with clients, and have aligned our strategies accordingly. Our expertise in Flexible Drug Development drives operational efficiency across the clinical development life cycle. Whether providing individual resources, outsourced functions, or in-sourced multi-functional teams, we enable companies to navigate the complexities of drug development with confidence, even in an unpredictable industry. #FlexibleDrugDevelopment #ConjugateGroup #Biopharma
-
Thank you so much Karen Lemire, MS, PMP! This kind of service is exactly what we strive for at Conjugate Group. David Pratt always takes a genuine, caring approach to representing professionals in our field, as do the other Resource Managers here. We are grateful to you for highlighting this, and grateful to David for representing you (and us) so well!
In the field of recruitment, there is a common trend of discontent among individuals regarding the recruiting process generally and recruiters specifically. However, amidst this backdrop, I would like to highlight a positive experience. For those navigating the job market in the biotech/pharma sectors, my interactions with Conjugate Group stand out as exceptional over the last ten years. CEO Andrew J. Young and recruiter David Pratt have set a high standard of professionalism, expertise, reliability, and trustworthiness. David's communication approach is characterized by openness, friendliness, and transparency, emphasizing the significance of strong recruiter-client relationships. At Conjugate Group, the policy strictly prohibits ghosting, ensuring a respectful and responsive recruitment experience. For anyone seeking a new opportunity, you would do well to contact David Pratt at Conjugate Group!
-
One of our fantastic clinical science consultants, Marjorie Zettler, PhD, MPH, penned an article outlining updated FDA guidance for dose optimization in drug development. It highlights how companies incorporating this kind of study design can provide a real benefit to their patient populations, particularly in the Oncology sector where tolerability and risk are massive drivers. Very much worth a read, and if your company is doing this, it would be great to hear about how it has shaped approval, uptake, and outcomes! https://lnkd.in/eDj2fc5N
-
Interesting story. We are seeing an increase in our clients asking for more face time. Not necessarily with our consultants but with our client decision makers. Though, at times our clients are asking for monthly face-to-face meetings with our consultants, dependent upon project/skill-set. We will see...
此处无法显示此内容
在领英 APP 中访问此内容等
-
I have been working with growing/emerging biopharma groups for over 25 years in the Boston/Cambridge area. At Conjugate Group, we speak with hundreds of industry leaders and professionals each week and see a larger picture, even trends/counter trends. With the reality of 2023 staring Conjugate in the face a year ago, I decided to use it as a growth year, building capability and staff to meet the returning demand of 2024/2025. As we get into the 3rd Quarter of 2024 its important to know what we are experiencing. We've realized strong growth using 1st Quarter of 2023 as a baseline. There are more requests for our clinical development and operations people, for example. This is good for that subset of professionals that were the most affected by the downturn in late 2022/2023. And remember: stability is not getting a job at any one firm be it Pfizer or Novartis, etc. Rather, I have always thought of stability being the sum of your skills, attitude and network. Network, perhaps, being the most key thing in the equation. If these 3 things are alive and growing, you will weather the storms of biotech every time. We are excited for 2025!